A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT05005273. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized Study of BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the safety and efficacy of BMS-986207 in combination with nivolumab and ipilimumab as first-line treatment for participants with stage IV non-small cell lung cancer (NSCLC).
Study identification
- NCT ID
- NCT05005273
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 1 participant
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2, 2022
- Primary completion
- Dec 26, 2022
- Completion
- Dec 26, 2022
- Last update posted
- Feb 27, 2024
2022
United States locations
- U.S. sites
- 17
- U.S. states
- 9
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0080 | Tucson | Arizona | 85719 | — |
| Local Institution - 0051 | Fountain Valley | California | 92708 | — |
| Local Institution - 0070 | Fort Myers | Florida | 33901 | — |
| Local Institution - 0073 | Gainesville | Florida | 32610 | — |
| Local Institution - 0036 | Orange City | Florida | 32763 | — |
| Local Institution - 0045 | Pensacola | Florida | 32504 | — |
| Local Institution | Port Saint Lucie | Florida | 34952 | — |
| Local Institution - 0068 | St. Petersburg | Florida | 33705 | — |
| Local Institution | Tallahassee | Florida | 32308 | — |
| Local Institution | West Palm Beach | Florida | 33401 | — |
| Local Institution - 0081 | Boise | Idaho | 83706 | — |
| Local Institution - 0077 | Coeur d'Alene | Idaho | 83214 | — |
| Local Institution - 0074 | Edgewood | Kentucky | 41017 | — |
| Local Institution - 0002 | Ann Arbor | Michigan | 48109 | — |
| Local Institution - 0049 | Brooklyn | New York | 11220 | — |
| Local Institution - 0012 | Charleston | South Carolina | 29414 | — |
| Local Institution - 0053 | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 54 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05005273, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 27, 2024 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05005273 live on ClinicalTrials.gov.